Drug Trial News

RSS

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

A new study offers some reassuring findings, reporting the successful neutralization of the South African SARS-CoV-2 variant of concern (VOC) 501Y.V2 by two vaccines developed in China.

4 Feb 2021

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

A new study reports the underlying basis of increased transmissibility in the N501Y UK variant and provides reassuring data on the efficacy of the Pfizer vaccine and Eli Lilly monoclonal antibodies in neutralizing it.

4 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

Nasodine antiseptic nasal spray shows potential antiviral activity against SARS-CoV-2

A team of international scientists has recently investigated the efficacy of PVP-1, a complex of polyvinylpyrrolidone and iodine, in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Using in vitro cell culture settings, the scientists observe that PVP-1 formulation used in a commercially available nasal spray (Nasodine) readily inactivates SARS-CoV-2 within a short period of time.

3 Feb 2021

Spark Therapeutics launches gene therapy clinical trial for late-onset Pompe disease

Pompe disease is a hereditary genetic disorder caused by a deficiency of acid alpha-glucosidase leading to build-up of glycogen in the lyosomes, which then causes cell damage in various tissues, in particular the heart, the muscles, the liver and the nervous system.

3 Feb 2021

Clinical trials of new treatments for COVID-19 often do not include vulnerable populations

Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.

3 Feb 2021

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today.

3 Feb 2021

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Researchers in the UK, South Africa and Brazil have reported the latest efficacy results from phase III trials of the Oxford–AstraZeneca vaccine currently being rolled out in the UK to protect against coronavirus disease 2019 (COVID-19).

3 Feb 2021

Experimental intranasal influenza vaccine produces durable immune response

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.

3 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

IONICON analyzers at the forefront of COVID-19 testing research

COVID-19 breath detection is studied around the globe using PTR-TOFMS.

From Ionicon Analytik Ges.m.b.H. 3 Feb 2021

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19.

2 Feb 2021

Study shows safety and effectiveness of two recommended ICU sedatives

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

2 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Now, a new preprint research paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The preprint is published on the bioRxiv server.

1 Feb 2021

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

Previous
1
...
58
59
60
61
62
63
64
...
1143
Next

Drug Trial News

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

Nasodine antiseptic nasal spray shows potential antiviral activity against SARS-CoV-2

Spark Therapeutics launches gene therapy clinical trial for late-onset Pompe disease

Clinical trials of new treatments for COVID-19 often do not include vulnerable populations

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Experimental intranasal influenza vaccine produces durable immune response

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

IONICON analyzers at the forefront of COVID-19 testing research

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

Study shows safety and effectiveness of two recommended ICU sedatives

Albumin: The Natural Choice for Diagnostic Tests

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News